ProQR Therapeutics (PRQR) Q3 2026 earnings review
ProQR enrolls its new drug trial fast, while costs rise
ProQR Therapeutics, a Dutch developer of RNA-editing medicines, enrolled its newest liver drug trial quickly while its cash burn rose. Operating cash outflow increased 11% to €13.6 million as research spending climbed, leaving €103 million in the bank. Chief executive Daniel A. de Boer completed enrollment for the first two groups in the AX-0811 trial, though initial results slipped from year-end to early January.
| Collaboration revenue | €5.2M +79% from a year ago |
|---|---|
| Research and development costs | €14.3M +29% from a year ago |
| Operating cash outflow | €13.6M +11% from a year ago |
| Cash runway outlook | Unchanged €103M cash funds operations into mid-2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because clinical progress on the main liver program balanced a minor readout delay and silent partner programs. Enrolling the first two groups of AX-0811 in under two months keeps the mid-2027 Phase 2 trial on schedule. One caution: the Eli Lilly partnership produced no milestones during the first nine months, and an $8 million Rett syndrome grant signed in 2024 still has not started.
The question now is whether the second-generation drug AX-0811 edits liver RNA more effectively in humans than the first-generation version did in June. If it shows stronger bile acid reductions at lower doses, ProQR can take a better medicine into patient trials; if not, the extra potency seen in laboratory tests did not carry over to people. The initial Phase 1 biomarker readout in early January 2027 will settle it.
🐂 Bull Case
Next-Generation Liver Drug Enrolls Fast
ProQR builds medicines using Axiomer, its platform for editing ribonucleic acid (RNA), the messenger molecules inside human cells. Its newest drug candidate is AX-0811, which blocks a liver protein called NTCP to stop toxic bile acids from building up inside liver cells. The company dosed the first volunteer in September, and the "first two cohorts of healthy volunteers are now fully enrolled", ProQR said.
Laboratory tests showed that AX-0811 has "greater potency and a longer half-life compared with AX-0810", its first-generation liver drug, the Dutch biotech group said. Because of those test results, management expects the new drug to beat the older version across three blood markers of bile acid processing. That matters because stronger performance would allow smaller doses and fewer injections for patients.
What to watch: the initial Phase 1 biomarker results for AX-0811 in early January 2027. Better bile acid readings than AX-0810 at matching doses would confirm that the newer drug works better in humans.
Three More Drug Candidates Near Human Trials
"Having established the first clinical validation of our Axiomer RNA editing platform, we are now expanding our pipeline on that foundation through several other programs that are entering clinical development," chief executive Daniel A. de Boer said. After proving in June that its first liver drug can edit RNA in healthy adults, the biotech company is increasing its lab spending to test more medicines.
- Research and development costs: €14.3 million, up 29.3% from a year ago
- Pediatric biliary atresia trial in China: starts in the first half of 2027, with initial patient results in the same period
- AX-0422 for Hurler syndrome, a rare genetic disorder: regulatory application in early 2027, initial patient results in the first half of 2027
- AX-2911 for fatty liver disease (MASH): human trial in China starts in the first half of 2027
Moving into patient studies matters because healthy volunteer trials only show that a drug hits its target, not that it treats an illness. What to watch: regulatory clearance for the AX-0422 patient trial in early 2027. Approval to dose patients would give ProQR its first test of fixing a broken gene rather than blocking a normal protein.
🐻 Bear Case
Initial AX-0811 Readout Slipped to January
In both the first and second quarters of this year, ProQR told investors to expect initial human test results for AX-0811 by the end of 2026. This quarter, de Boer pushed that schedule back, stating that the company now expects to report "initial AX-0811 data in early January 2027".
A delay of a few weeks is small, so it does not change the drug's long-term potential. However, ProQR plans to start a larger Phase 2 trial for its liver franchise in mid-2027, and it needs the AX-0811 data to pick the winning drug and talk with regulators. Any further delay would compress the time available to prepare that mid-year trial.
What to watch: the presentation of full Phase 1 results for AX-0810 and laboratory data for AX-0811 in December 2026. That presentation will show whether the 12-week follow-up on the older drug stays clean before the January readout.
Lilly Deferred Revenue Shrinks Without Milestones
ProQR has no approved drugs on the market, so all of its €5.2 million in third-quarter revenue came from its research partnership with pharmaceutical giant Eli Lilly. The company books its past upfront cash from Lilly as revenue over time based on the "percentage of labor hours incurred compared to the total estimated labor hours required", ProQR said in its financial notes.
Consequently, revenue growth of 78.9% from a year ago only means ProQR worked more hours on the project, bringing in no new cash. Meanwhile, the remaining balance of unearned Lilly funds dropped by €5.2 million from last quarter to €23.0 million, by our math. During the first nine months of 2026, the company "did not reach any milestones under the agreement", ProQR wrote, against $4.5 million earned in 2025.
What to watch: milestone payments or an extension before the five-year Lilly research term ends on December 21, 2027. Without a compound handover or a $50 million expansion option, collaboration revenue will run out next year.
Rett Syndrome Trial Funding Remains Uncollected
In December 2024, ProQR expanded its partnership with the Rett Syndrome Research Trust (RSRT) to include $8.15 million in new funding to move its Rett syndrome drug candidate, AX-2402, into human clinical trials. At the end of 2025, the company aimed to begin human testing for that neurological program in the first half of 2027.
Nearly two years after signing the funding deal, "no amounts have been received under this agreement and the work has not yet commenced", the company disclosed in Note 14. In addition, the third-quarter press release dropped AX-2402 from its list of upcoming 2027 clinical milestones. That silence suggests the Rett syndrome program has stalled behind the liver and Hurler syndrome candidates.
What to watch: grant income and deferred income from RSRT in the fourth-quarter report. A zero balance at year-end would confirm that clinical work on AX-2402 will not start in the first half of 2027.
👓 Other Themes
AI Leadership Hires Expand Discovery Team
In September, ProQR hired Chris Hart as Chief Data and AI Officer and named Hugging Face co-founder Thomas Wolf as a board advisor. Hart previously led data science and machine learning for genetic medicines at Eli Lilly. These appointments follow an April deal where the company issued 3.0 million shares to Ginkgo Bioworks for $5.0 million in future laboratory credits to support its artificial intelligence discovery engine.
💲 Other KPIs
Cash used in operating activities rose 11.0% from a year ago and 10.7% from last quarter as clinical trial spending increased. ProQR ended September with €103.0 million in cash and cash equivalents, down from €117.1 million in June following the second-quarter share sale.
The basic and diluted share count jumped 34.1% from a year ago and 28.4% from the second quarter. The increase reflects the full-quarter impact of the 32.7 million shares sold to public investors and Eli Lilly in late June 2026, plus 3.0 million shares issued to Ginkgo Bioworks in April.
Overhead expenses rose 27.2% from €3.1 million a year ago, driven by higher employee share-based compensation, which reached €2.9 million for the first nine months of 2026 versus €2.0 million in the prior-year period. Compared with the second quarter's €4.9 million, overhead spending fell 19.3%.
🔮 Guidance
Unchanged. Management expects its €103.0 million cash pile to fund operations "supporting runway into mid-2028", ProQR said. At the third quarter's total cash burn of €14.3 million, €103.0 million covers roughly seven quarters of spending by our math, matching the company's timeline through the middle of 2028.
Pushed back. The company now plans to release initial target engagement data from the first two healthy volunteer groups in early January 2027, rather than by the end of 2026 as stated in the first and second quarters. Both groups have finished enrolling participants.
Unchanged. Subject to discussions with regulators, the biotech group still plans to start a Phase 2 clinical trial in mid-2027 that could support drug approval, with a first interim data readout in mid-2028. An investigator-run study in children with biliary atresia in China is also still set to start and report initial data in the first half of 2027.
❓ Key Questions
Why has work not started under the RSRT grant?
ProQR signed an $8.15 million clinical funding expansion with the Rett Syndrome Research Trust in December 2024, yet Note 14 states that work has not commenced and AX-2402 disappeared from the milestone list.
Will the Dutch government extend the Innovation credit waiver?
The company owes €5.1 million in principal and accrued interest on a government loan for its discontinued eye program. The repayment waiver expires on December 31, 2026, and a forced payoff would reduce cash.
How close is the Eli Lilly collaboration to a milestone?
ProQR booked $4.5 million in Lilly milestones during 2025 but zero in the first nine months of 2026, while the remaining deferred revenue balance fell to €23.0 million ahead of the December 2027 contract end.
How much of the Ginkgo Bioworks credit has been used?
ProQR issued 3.0 million shares to Ginkgo in April 2026 for a $5.0 million service credit, but the financial notes do not disclose how much of that credit was expensed into research costs this quarter.